9 News & Press Releases found

Exact Sciences UK, Ltd. news

New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making

Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy

Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented

Dec. 9, 2021

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
Results have already led to updated NCCN Guidelines® for breast cancer
New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast Cancer Symposium (SABCS)

Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Pos

Dec. 2, 2021

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in Node-Positive Early-Stage Breast Cancer

Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment
Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemotherapy

Exact Sciences today announced results from a health economic analysis of the Oncotype DX Breast Recurrence Score® test, accepted at the 2021 American Society of Clinica

May. 20, 2021

New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network (NCCN)ii in its updated guidelines for breast cancer. iii The Oncotype DX test is now the only test classified as “preferred” with the highest level of evidence

Mar. 25, 2021

RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium
RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease

Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully

Dec. 9, 2020